Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-10-17
2006-10-17
Nickol, Gary (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S391100, C530S387300
Reexamination Certificate
active
07122636
ABSTRACT:
Described are conjugates formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also described are conjugates directed against human vascular endothelial growth factor (VEGF), human p185 receptor-like tyrosine kinase (HER2), human CD20, human CD18, human CD11a, human IgE, human apoptosis receptor-2 (Apo-2), human tumor necrosis factor-α (TNF-α), human tissue factor (TF), human α4β7 integrin, human GPIIb-IIIa integrin, human epidermal growth factor receptor (EGFR), human CD3, and human interleukin-2 receptor α-chain (TAC) for diagnostic and therapeutic applications.
REFERENCES:
patent: 4002531 (1977-01-01), Royer
patent: 4179337 (1979-12-01), Davis et al.
patent: 4515893 (1985-05-01), Kung et al.
patent: 4732863 (1988-03-01), Tomasi et al.
patent: 5091313 (1992-02-01), Chang
patent: 5147537 (1992-09-01), Sada et al.
patent: 5166322 (1992-11-01), Shaw et al.
patent: 5169627 (1992-12-01), Cunningham-Rundles
patent: 5527528 (1996-06-01), Allen et al.
patent: 5532150 (1996-07-01), Snow et al.
patent: 5595732 (1997-01-01), Hakini et al.
patent: 5618920 (1997-04-01), Robinson et al.
patent: 5620689 (1997-04-01), Allen et al.
patent: 5622700 (1997-04-01), Jardieu et al.
patent: 5643575 (1997-07-01), Martinez et al.
patent: 5661020 (1997-08-01), Snow et al.
patent: 5670132 (1997-09-01), Griffiths et al.
patent: 5672347 (1997-09-01), Aggarwal et al.
patent: 5677426 (1997-10-01), Fong et al.
patent: 5679532 (1997-10-01), Repine
patent: 5686070 (1997-11-01), Doerschuk et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5695760 (1997-12-01), Faanes et al.
patent: 5698196 (1997-12-01), Matsushima et al.
patent: 5702946 (1997-12-01), Doerschuk et al.
patent: 5707622 (1998-01-01), Fong et al.
patent: 5714338 (1998-02-01), Wai Fei et al.
patent: 5725856 (1998-03-01), Hudziak et al.
patent: 5726037 (1998-03-01), Bodary et al.
patent: 5766897 (1998-06-01), Braxton
patent: 5874080 (1999-02-01), Hebert et al.
patent: 6133426 (2000-10-01), Gonzalez et al.
patent: 0239400 (1987-09-01), None
Zepata et al., FASEB J. 9:A1479, abstract 1288, 1995.
Harlow et al., Antobodies A Laboratory Manual, Cold Spring Harbor Laboratory, 1988.
Haber, Biochemistry 52:1099-1106, 1964.
Tout et al., Clinical and Diagnostic Laboratory Immunol. 4:147-155, 1997.
Cruse et al (Illustrated Dictionary of Immunology, CRC Press, p. 107, 1995).
Cruse et al, (Illustrated Dictionary of Immunolgy, CRC Press, p. 107, 1995.
Abuchowski and Davis, “Soluble Polymer- Enzyme Adducts”Enzymes as Drugs, Holcenberg,JS; Roberts,J eds., New York:Wiley, Chapter 13, pp. 367-383 (1981).
Adagen LabelPhysicians' Desk Reference(Product Information), 48 edition, Montvale, NJ:Medical Economics Data Production Company pp. 917-918 (1994).
Allen et al., “A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells”Biochimica et Biophysica Acta1237(2):99-108 (Jul. 26, 1995).
Anderson and Tomasi, “Polymer modification of antibody to eliminate immune complex and Fc binding”Journal of Immunological Methods109(1):37-42 (Apr. 22, 1988).
Beauchamp et al., “A new procedure for the synthesis of polyethylene glycol-protein adducts; effects on function, receptor recognition, and clearance of superoxide dismutase, lactoferrin, and α2-macroglobulin”Analytical Biochemistry131(1):25-33 (1983).
Bernard et al., “The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination”American Journal of Respiratory & Critical Care Medicine149(3 Pt 1):818-824 (Mar. 1994).
Brooks and Stocks, “Use of polyacrylamide-derivatized antibody in dextran-poly(ethylene glycol) systems”Methods in Enzymology228:390-395 (1994).
Brumeanu et al., “Derivatization with monomethoxypolyethylene glycol of Igs expressing viral epitopes obviates adjuvant requirements”Journal of Immunology154(7):3088-3095 (Apr. 1, 1995).
Carter et al., “Preparation and uses of Fab' fragments fromEscherichia coli” Antibody Engineering: a Practical Approach, Hoogenboom, H., McCafferty, J., Chiswell, D. eds., Oxford, UK:IRL Press, Chapter 13, pp. 291-308 (1996).
Chamow et al., “Modification of CD4 immunoadhesin with monomethoxypoly(ethylene glycol) aldehyde via reductive alkylation”Bioconjugate Chemistry5(2):133-140 (Mar.-Apr. 1994).
Chapman et al., “Therapeutic antibody fragments with prolonged in vivo half-lives”Nature Biotechnology17(8):780-783 (Aug. 1999).
Clark et al., “Long-acting growth hormones produced by conjugation with polyethylene glycol”Journal of Biological Chemistry271(36):21969-21977 (Sep. 6, 1996).
Cunningham-Rundles et al., “Biological activities of polyethylene-glycol immunoglobulin conjugates. Resistance to enzymatic degradation”Journal of Immunological Methods152(2):177-190 (Aug. 10, 1992).
Davis et al., “Soluble, Nonantigenic Polyethylene Gylcol-Bound Enzymes”Biomedical Polymers: Polymeric Materials and Pharmaceuticals for Biomedical Use, Goldberg,E and Nakajima,A eds., New York:Academic Press pp. 441-452 (1980).
Delgado et al., “Analytical partitioning of poly(ethylene glycol)-modifed proteins”Journal of Chromatography B692(2):263-272 (May 9, 1997).
Delgado et al., “Distinct Influence of PEGylation on the Tumor Localisation of Transferrin and a Tumour-Specific Fab Fragment (F9)”Journal of Cellular Biochemistry(Abstr. A4-101, Keystone Symposium held at Hilton Head Island, SC, Jan. 7-13, 1995) Suppl. 19A:171 (1995).
Delgado et al., “Enhanced tumour specificity of an anti-carcinoembrionic antigen Fab' fragment by poly(ethylene glycol) (PEG) modification”British Journal of Cancer73(2):175-182 (Jan. 1996).
Delgado et al., “The uses and properties of PEG-linked proteins”Critical Reviews in Therapeutic Drug Carrier Systems9(3-4):249-304 (1992).
Deuel et al., “Amino acid sequence of human platelet factor 4”Proc. Natl. Acad. Sci.74:2256-2258 (1977).
Donnelly et al., “Interleukin-8 and development of adult respiratory distress syndrome in at-risk patient groups”Lancet341(8846):643-647 (Mar. 13, 1993).
Elling and Kula, “Immunoaffinity partitioning: synthesis and use of polyethylene glycol-oxirane for coupling to bovine serum albumin and monoclonal antibodies”Biotechnology and Applied Biochemistry13(3):354-362 (Jun. 1991).
Eno-Amooquaye et al., “Altered biodistribution of an antibody-enzyme conjugate modified with polyethylene glycol”British Journal of Cancer73(11):1323-1327 (Jun. 1996).
Folkesson et al., “Acid aspiration-induced lung injury in rabbits is mediated by interleukin-8-dependent mechanisms”Journal of Clinical Investigation96(1):107-116 (Jul. 1995).
Gonzalez et al., “Humanization of Murine 6G425:An Anti-IL8 Monoclonal Antibody Which Blocks Binding of IL8 to Human Neutrophils”1996 Keystone Symposia on Exploring and Exploiting Antibody and Ig Superfamily Combining Sites(Poster) pp. 1-21 (Feb. 1996).
Harding et al., “Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes”Biochimica et Biophysica Acta1327(2):181-192 (Jul. 25, 1997).
Harris et al., “Synthesis and Characterization of Poly(ethylene Glycol) Derivatives”J. Polym. Sci., Polym. Chem. Ed.22(2)341-352 (1984).
Haselgrubler et al., “Synthesis and applications of a new poly(ethylene glycol) derivative for the crosslinking of amines with thiols”Bioconjugate Chemistry6(3):242-248 (May-Jun. 1995).
Hebert et al., “Endothelial and Leukocyte Forms of IL-8: Conversion by Thrombin and Interactions with Neutrophils&
Hsei Vanessa
Koumenis Iphigenia
Leong Steven
Shahrokh Zahra
Zapata Gerardo
Aeder Sean E
Dreger Ginger R.
Fox James A.
Genentech Inc.
Nickol Gary
LandOfFree
Antibody fragment-polymer conjugates and uses of same does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibody fragment-polymer conjugates and uses of same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibody fragment-polymer conjugates and uses of same will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3716893